Etanercept-Induced Interstitial Lung Disease in a Patient with Plaque Psoriasis
Etanercept is one of the biologic drugs approved for the treatment of psoriasis. Despite its wide use and proven efficacy, few cases of pulmonary toxicity have been reported.
We present a patient with psoriasis vulgaris medicated with etanercept. Seven months after its start, the patient developed productive cough, with no fever or constitutional symptoms. The thoracic computerized tomography revealed a pattern of bilateral dense micronodules, with predominance in the superior lobes. After suspension of etanercept, there was symptomatic and imaging resolution, without the need for additional pharmacological treatment. We switched the biologic agent for ustekinumab, with good
tolerance and high efficacy.
European Medicines Agency. Summary of Product Characteristics Enbrel [acedido a 05 de agosto de 2019] Disponível em: https://www.ema.europa.eu/documents/product-information/enbrel-epar-product-information-en.pdf.
Cunnane G, Warnock M, Fye K, Daikh D. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:445-9. Doi: 10.1002/art.10535.
Zamora F, Podgaetz E, Dincer H. Nódulos pulmonares contraintuitivos en artritis reumatoide. Arch Bronconeumol. 2016;52:334-5. doi: 10.1016/j.arbres.2015.09.010.
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa J, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-
-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256-64. doi: 10.1016/j.semarthrit.2010.11.002.
Wynn T. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol. 2004;4:583-94.
Serban K, Muzoora M, Hage C, Lahm T. Distinct immunologic and radiographic patterns in etanercept-induced lung injury. Respir Med Case Rep. 2013;8:18-20. doi: 10.1016/j.rmcr.2012.12.002.
Copyright (c) 2019 Journal of the Portuguese Society of Dermatology and Venereology
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles in this journal are Open Access and meet the requirements of funding bodies or academic institutions. Each article published in the Journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). Articles can be read, downloaded, printed, and shared.
Submission of an article for publication implies the authors’ consent to publication under the applicable Creative Commons license and the terms and conditions of the Publisher’s Licensing Agreement.
It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement'. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Author rights: As an author you (or your employer or institution) have certain rights to reuse your work.
The Journal reserves the right to use plagiarism detection software on any submitted material.